Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $8
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $6 to $8.
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $6 to $8.